ReoPro cuts angioplasty complications in half:
This article was originally published in Clinica
Executive Summary
Centocor's antithrombotic drug ReoPro cut heart attacks and death six months after angioplasty by 46% in the EPILOG trial (Evaluation of PTCA to Improve Long-Term Outcome by c7E3 GP IIb/IIIa Receptor Blockade). At the same time it reduced the need for emergency revascularisation by 53.7%, said chairman of the Cleveland Clinic's cardiology department Dr Eric Topol. ReoPro inactivates IIb/IIIa binding sites on the surface of blood platelets.
You may also be interested in...
Moderna Files COVID-19 Vaccine After Second Impressive Read-Out
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: